Continuing Education Activity

Solar urticaria is a rare chronic inducible urticaria precipitated by exposure to UV or visible light. Onset typically occurs within minutes of exposure and manifests as erythematous, pruritic wheals confined to exposed skin, often accompanied by burning or stinging sensations. Severe reactions may include headache, nausea, wheezing, or syncope when extensive skin surfaces are involved. Symptoms generally resolve within 1 to 2 hours after exposure cessation without residual pigmentation or scarring. Pathogenesis is attributed to a type I hypersensitivity reaction in which photoactivation of an endogenous chromophore generates a photoallergen that triggers immunoglobulin E–mediated mast cell degranulation and histamine release.

Diagnosis is clinical and supported by phototesting with defined wavelengths to identify the action spectrum. Differential diagnoses include polymorphic light eruption, photoallergic dermatitis, and lupus erythematosus. Management emphasizes photoprotection using broad-spectrum sunscreens, protective clothing, and avoidance of triggering wavelengths. Nonsedating H1-antihistamines remain the 1st-line pharmacologic therapy and may require higher-than-standard dosing. Refractory disease may respond to desensitization via graded phototherapy, omalizumab (anti-immunoglobulin E monoclonal antibody), or immunosuppressive agents such as cyclosporine. Prognosis is variable. Spontaneous remission occurs in some cases, whereas others exhibit persistent, recurrent disease with substantial quality-of-life impairment.

This activity for healthcare professionals is designed to enhance learners' competence in evaluating and managing solar urticaria. Participants will advance their mastery of this dermatologic condition's etiology, risk factors, pathophysiology, clinical presentation, and best diagnostic and therapeutic practices. Improved skills will equip clinicians to collaborate with interprofessional teams involved in the care of affected individuals.

Objectives:

• Identify the clinical and diagnostic findings suggestive of solar urticaria.
• Implement best practices for managing solar urticaria and preventing its potential sequelae.
• Improve patient understanding of solar urticaria, including triggers, photoprotection strategies, symptom recognition, and adherence to therapy, to enhance self-management and long-term outcomes.
• Apply effective strategies to improve care coordination among interprofessional team members to facilitate positive outcomes for patients with solar urticaria.

Access free multiple choice questions on this topic.

Introduction

Solar urticaria is a chronic acquired photosensitivity disorder characterized by recurrent urticarial eruptions on skin exposed to sunlight.[1] Although typically benign, the condition can be severely disabling, limiting daily activities and markedly reducing quality of life.[2][3][4][5] Diagnosis is primarily clinical, supported by phototesting to identify the action spectrum and minimal urticarial dose. Symptoms and distribution may mimic other acquired photodermatoses, including polymorphous light eruption, drug-induced photosensitivity, and photocontact dermatitis.

Etiology

Exposure of the skin to sunlight can trigger solar urticaria.[6] The action spectrum—the wavelengths capable of eliciting reactions—spans ultraviolet B to visible light (300–500 nm) and is patient-specific.[7]

Epidemiology

Solar urticaria is an uncommon form of urticaria, accounting for less than 0.5% of all urticaria cases and 7% of photodermatoses. The condition typically begins in young adulthood, with a median age of 35 years, although onset in neonates and older adults has been reported. A female predominance exists, with no apparent ethnic differences. In the largest series, a history of atopy was reported in fewer than 30% of cases. Coexistence with other types of chronic urticaria occurs in up to 16% of patients.[8][9]

Pathophysiology

Solar urticaria is a rare, immunologically mediated photodermatosis in which activation of cutaneous mast cells is triggered by specific wavelengths of solar electromagnetic radiation.[10] The pathophysiology of solar urticaria is not fully understood. The condition is an immediate hypersensitivity reaction, potentially mediated by immunoglobulin E (IgE), occurring after sunlight exposure. Radiation may activate an endogenous substance, the chromophore, present in serum or dermis, converting it into an immunologically active photoallergen. This process induces mast cell degranulation, producing urticarial lesions. A positive intradermal reaction following injection of the patient’s irradiated serum supports the circulating chromophore hypothesis.

Certain radiation wavelengths, typically longer ones, may inhibit the immunologic reaction induced by shorter wavelengths. This phenomenon is termed the "double spectrum of action."[11] Exogenous substances, including medications such as atorvastatin, chlorpromazine, tetracycline, and oral contraceptives, occasionally trigger solar urticaria.[12][13][14]

Histopathology

The histopathology of solar urticaria closely resembles that of other urticarias. The dermis exhibits mild edema with a perivascular mixed infiltrate of neutrophils and eosinophils.

History and Physical

Erythema and edematous papules develop within minutes of sunlight exposure on sun-exposed areas and even on skin covered by thin, light-colored clothing that permits penetration of solar radiation. Covered skin may react more severely once directly exposed. The face and hands appear relatively more tolerant to sunlight. The rash is accompanied by itching or burning. Periorbital or mucosal angioedema may also occur, and dermographism is observed in some patients.

Systemic symptoms, including nausea, wheezing, dyspnea, or syncope, are not uncommon, particularly when large areas of skin are exposed for prolonged periods. Anaphylactic shock is rare, even when systemic symptoms are present. Cutaneous manifestations resolve within an hour in approximately 75% of cases following cessation of sun exposure and typically disappear completely within 24 hours. Symptom severity and duration correlate with light intensity.

Evaluation

The diagnosis of solar urticaria is suspected based on anamnesis, characterized by transient urticarial lesions appearing within minutes of sunlight exposure, while physical examination is typically unremarkable in the absence of exposure. Symptoms and lesion distribution may mimic other acquired photodermatoses. Differential diagnoses include polymorphous light eruption, lupus erythematosus, drug-induced photosensitivity, and photocontact dermatitis. Solar urticaria may also coexist with other photodermatoses, such as polymorphous light eruption and porphyria cutanea tarda.

Confirmation requires phototesting using UVA, UVB, and visible light sources. Natural sunlight may be employed in some cases. Phototesting determines the action spectrum, which refers to the wavelengths that trigger the reaction, and the minimal urticarial dose, which is the smallest amount of radiation that induces an urticarial response. Identifying the action spectrum is essential for guiding subsequent management and ensuring patients avoid the specific triggering wavelengths.

Light sources are positioned 10–15 cm from the patient, and varying radiation doses are administered. Clinical response is evaluated every 10 minutes for an hour. Erythema and wheals develop immediately after phototesting and typically resolve within minutes after cessation of radiation. In many cases, phototesting with artificial light sources is noncontributory, as cutaneous lesions may occur only in response to natural sunlight. Repeating phototesting may yield positive results in some patients.

Histopathological examination may be performed to exclude other photodermatoses. Solar urticaria exhibits classic urticarial features, including endothelial swelling and dermal infiltration by neutrophils, monocytes, and eosinophils. Photopatch testing may assist in excluding drug-induced photosensitivity or photocontact dermatitis.

Treatment / Management

No formal guidelines have been established for the treatment of solar urticaria. Many therapies have been employed with variable success. Sun exposure avoidance is recommended, along with photoprotection using broad-spectrum sunscreens and protective clothing.[15][16][17]

By analogy with idiopathic chronic urticaria, 2nd-generation H1 receptor antagonists are widely used and generally accepted as 1st-line therapy. Agents include loratadine, fexofenadine, and cetirizine. These medications provide relief in most cases but often require 2- to 4-fold higher doses than standard regimens. Second-generation H1 receptor antagonists appear more effective in delayed-onset urticaria but do not reduce erythema in solar urticaria.

Since chronically exposed areas develop relative tolerance to sunlight, phototherapy (using UVA, UVB, or visible light) and photochemotherapy (ie, psoralen plus UVA or "PUVA") have been used to induce hardening. This process should be guided by the action spectrum and minimal urticarial dose. PUVA appears to provide longer-lasting effects than phototherapy alone.

Intravenous immunoglobulins, cyclosporine, afamelanotide, and omalizumab have demonstrated some efficacy in refractory cases. Oral steroids, leukotriene receptor antagonists, antimalarial agents, prostaglandin inhibitors, and oral β-carotene show minimal or no benefit. Combination therapies are often required to achieve and maintain clinical improvement. Recently, a few cases have been reported in which solar urticaria was treated with serial plasmapheresis.[18]

Differential Diagnosis

Differential diagnosis includes polymorphous light eruption, lupus erythematosus, drug-induced photosensitivity, and photocontact dermatitis. Solar urticaria may also coexist with other photodermatoses, such as polymorphous light eruption and porphyria cutanea tarda.

Prognosis

Solar urticaria is an enigmatic disorder with a poorly understood pathophysiology. Although diagnosis is straightforward, management is challenging. The condition typically develops in the 3rd decade of life and often follows a chronic course. Symptoms are managed using various therapies, but remission depends on a phenomenon known as hardening, which is not achieved in all patients. "Hardening" refers to the process by which repeated UV exposure reduces the likelihood of urticarial attacks. The probability of spontaneous resolution has been estimated at 15% at 5 years and 25% at 10 years after disease onset.[19]

Overall, the prognosis for patients with severe solar urticaria is poor. Many remain confined indoors, resulting in a substantially reduced quality of life.

Complications

Complications of solar urticaria primarily result from the intensity and chronicity of the photosensitivity response. Acute complications include extensive whealing, angioedema, and, in severe cases, systemic manifestations such as hypotension, syncope, or anaphylactoid reactions following widespread light exposure. Chronic disease may cause significant psychological morbidity, including anxiety, depression, and social withdrawal, due to the unpredictable and disabling nature of the condition. Persistent photoprotection and lifestyle modifications can lead to vitamin D deficiency and secondary osteopenia. Additionally, patients often develop secondary dermatitis from excessive sunscreen use or irritant contact reactions.

Deterrence and Patient Education

As with other photosensitivity disorders, patients must be advised to avoid and protect against UV radiation. Use of broad-spectrum sunscreen applied liberally to sun-exposed areas, wide-brimmed hats, and clothing providing adequate coverage should be emphasized to prevent attacks of solar urticaria.

Pearls and Other Issues

Solar urticaria often follows a chronic course. Approximately 1/2 of patients remain symptomatic 10 to 15 years after disease onset. Longer duration of symptoms before the 1st medical evaluation and age over 40 years are associated with a more prolonged course. Patients whose reactivity is limited to visible or natural light appear to have the most favorable prognosis.

Enhancing Healthcare Team Outcomes

Solar urticaria is a perplexing disorder with a poorly understood pathophysiology. Although diagnosis is straightforward, management is complex. The condition is often encountered by primary care providers, nurse practitioners, dermatologists, and internists. Referral to a dermatologist is recommended since solar urticaria can be difficult to distinguish from other pruritic disorders, as mentioned.

No formal treatment guidelines are currently defined. Different therapies have been employed with variable success. High-dose 2nd-generation antihistamines, sun exposure avoidance, broad-spectrum sunscreens, and protective clothing are currently considered 1st-line.

Patients who fail conservative therapy may be managed with phototherapy or biologic agents. Overall, the prognosis for patients with severe solar urticaria is poor. Many remain confined indoors, resulting in a significantly reduced quality of life.[20]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

McSweeney SM, Kloczko E, Chadha M, Sarkany R, Fassihi H, Tziotzios C, McGrath JA. Systematic review of the clinical characteristics and natural history of solar urticaria. J Am Acad Dermatol. 2023 Jul;89(1):138-140. [PubMed: 36796725]

2.

Milanesi N, Gola M, Francalanci S. Evaluation of nine patients with solar urticaria during summer. G Ital Dermatol Venereol. 2020 Dec;155(6):800-802. [PubMed: 30924623]

3.

Snast I, Lapidoth M, Uvaidov V, Enk CD, Mazor S, Hodak E, Levi A. Real-life experience in the treatment of solar urticaria: retrospective cohort study. Clin Exp Dermatol. 2019 Jul;44(5):e164-e170. [PubMed: 30828851]

4.

Photiou L, Foley P, Ross G. Solar urticaria - An Australian case series of 83 patients. Australas J Dermatol. 2019 May;60(2):110-117. [PubMed: 30585308]

5.

Lyons AB, Peacock A, Zubair R, Hamzavi IH, Lim HW. Successful treatment of solar urticaria with UVA1 hardening in three patients. Photodermatol Photoimmunol Photomed. 2019 May;35(3):193-195. [PubMed: 30576021]

6.

Balakirski G, Gäbelein-Wissing N, Hofmann SC. [Solar urticaria and polymorphous light eruption]. Dermatologie (Heidelb). 2024 Jul;75(7):518-527. [PubMed: 38864900]

7.

Snyder M, Turrentine JE, Cruz PD. Photocontact Dermatitis and Its Clinical Mimics: an Overview for the Allergist. Clin Rev Allergy Immunol. 2019 Feb;56(1):32-40. [PubMed: 29951786]

8.

Fityan A, McGibbon D, Fassihi H, Sarkany RS. Paediatric solar urticaria: a case series. Br J Dermatol. 2018 Jun;178(6):1453-1454. [PubMed: 29315482]

9.

Raigosa M, Toro Y, Sánchez J. [Solar urticaria. Case report and literature review]. Rev Alerg Mex. 2017 Jul-Sep;64(3):371-375. [PubMed: 29046033]

10.

McSweeney SM, Sarkany R, Fassihi H, Tziotzios C, McGrath JA. Pathogenesis of solar urticaria: Classic perspectives and emerging concepts. Exp Dermatol. 2022 Apr;31(4):586-593. [PubMed: 34726314]

11.

Ross HE, Parkin D, Ayer J. Overexposure to ultraviolet radiation in solar urticaria. BMJ Case Rep. 2024 May 09;17(5) [PubMed: 38724216]

12.

Griffin LL, Haylett AK, Rhodes LE. Evaluating patient responses to omalizumab in solar urticaria. Photodermatol Photoimmunol Photomed. 2019 Jan;35(1):57-65. [PubMed: 30338865]

13.

Chicharro P, Rodríguez-Jiménez P, Capusan TM, Herrero-Moyano M, de Argila D. Induction of Light Tolerance Using Narrowband UV-B in Solar Urticaria. Actas Dermosifiliogr (Engl Ed). 2018 Dec;109(10):888-892. [PubMed: 30205902]

14.

Farr PM. Erythropoietic protoporphyria and solar urticaria. Br J Dermatol. 2018 Aug;179(2):542. [PubMed: 29683481]

15.

Maurer M, Fluhr JW, Khan DA. How to Approach Chronic Inducible Urticaria. J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1119-1130. [PubMed: 30033913]

16.

Snast I, Kremer N, Lapidoth M, Enk CD, Tal Y, Rosman Y, Confino-Cohen R, Hodak E, Levi A. Omalizumab for the Treatment of Solar Urticaria: Case Series and Systematic Review of the Literature. J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1198-1204.e3. [PubMed: 29572192]

17.

Morgado-Carrasco D, Fustà-Novell X, Podlipnik S, Combalia A, Aguilera P. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature. Photodermatol Photoimmunol Photomed. 2018 May;34(3):194-199. [PubMed: 29171925]

18.

Boontaveeyuwat E, Willis F, Fassihi H, Sarkany RPE. Successful serial plasmapheresis for solar urticaria, a case report and literature review. J Dermatolog Treat. 2024 Dec;35(1):2350229. [PubMed: 38880493]

19.

Beattie PE, Dawe RS, Ibbotson SH, Ferguson J. Characteristics and prognosis of idiopathic solar urticaria: a cohort of 87 cases. Arch Dermatol. 2003 Sep;139(9):1149-54. [PubMed: 12975156]

20.

Haylett AK, Koumaki D, Rhodes LE. Solar urticaria in 145 patients: Assessment of action spectra and impact on quality of life in adults and children. Photodermatol Photoimmunol Photomed. 2018 Jul;34(4):262-268. [PubMed: 29533487]

Disclosure: Hasnain Syed declares no relevant financial relationships with ineligible companies.

Disclosure: Jonathan Crane declares no relevant financial relationships with ineligible companies.

Disclosure: Blair Harris declares no relevant financial relationships with ineligible companies.

Disclosure: Joel Schlessinger declares no relevant financial relationships with ineligible companies.